As Rare Disease Day approaches on February 29th, it’s a moment for reflection, awareness, and most importantly, unity. In the vast landscape of medical conditions, some are so rare that…
Due to the Pre-Clinical Data and Initial Clinical Data from Cardiol’s Maverick-Pilot Phase II Study of Pericarditis, it has been granted Orphan Drug Designation for its lead drug candidate for…
Welcome to the Myocarditis Foundation’s educational resource aimed at shedding light on a commonly misunderstood cardiac condition: pericarditis. We share a YouTube video created by Zero to Finals, designed to…
We are thrilled to share some exciting news with you! Once again, the Myocarditis Foundation has achieved the prestigious Platinum Transparency Certification from Candid (formerly GuideStar), a leading non-profit reporting…
Cardiogenic shock (CS) is a low cardiac output state resulting in tissue hypoxia and life threatening end-organ hypoperfusion. Despite growing cardiogenic shock research in adults, the epidemiology, clinical features, and…
Dr. Javid Moslehi, MD, has recently been appointed to the Myocarditis Foundation’s Medical Advisory Board. He has a very impressive CV and was recently appointed as the Director of Myocarditis…
First, I would like to introduce Dr. Dor Lotan. He is a heart failure cardiologist who specializes in advanced heart failure therapies and cardiomyopathies. He has a special interest in…
Our second 2023 Fellowship Grants was awarded to Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinc for his work on: “Leveraging Cutting-edge PHlP-Seq Antibody Profiling to Differentiate Autoantibody…
One of the 2023 Fellowship Grants was awarded to Dr. Swati Sharma, of the University of North Carolina, Chapel Hill, for her work on: “The Protective Role of Platelet Protease-activated…
It is with deep sadness that we share the passing of one of our long-standing members of our Board of Directors, Joel Aranson. Joel joined the Myocarditis Foundation’s Board of…
